Ascend is built on a simple philosophy: high quality science can be translated into leading edge products.
Ascend is a clinical-stage company developing innovative cancer treatments. We focus on identifying disease settings where targeting the disease microenvironment or key cell types has the potential to bring about meaningful improvements in clinical outcomes.
We have two clinical stage immunotherapy programs which have undergone significant clinical study.
Our first product, ASN-002, is a treatment designed for direct delivery into tumours and clinical trials will commence with basal cell carcinoma, the most common form of skin cancer worldwide.
Our second product, ASN-004, is a pan-cancer treatment that is based on a well validated platform technology. We have recently improved the drug composition and expect to commence a trial of the drug in patients with early stage breast cancer.
We are also developing a next-generation platform that aims to target and deliver genes to specific cell types or anatomical locations. These drugs are designed to be injected into the blood and can selectively home in to important disease locations and express therapeutic genes for extended periods.